In close collaboration with renowned academic experts, we generate in vivo validated sequences which are then formulated with our BIO-COURIER technology to promptly translate them into safe, and effective treatments available to patients worldwide. We’ve also developed an allied RNA thermostability technology, COLHYSILICTM, to permit the long-term ambient storage of RNA therapeutics and escape the access limitations of ultracold chain storage.
SiSaf is a UK-based private company, with fully integrated research labs, bio-analytical facilities, and a scaled technology to fast-track development. We have a FTSE 100 strategic partner and a robust and growing patent estate.
